Nevertheless, it is important to consider that VHL mutations can lead to false-positive results on SDHB immunohistochemistry (34); therefore, we recommend that those patients with RAPTAS, without a detectable germline mutation in SDHx, but with loss of SDHB immunoexpression on tumor studies, undergo genetic screening for VHL mutations (Fig. 3). This evidence concerns the gene VHL and neoplasm.